Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088676 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6823 (Electronic) Linking ISSN: 14726823 NLM ISO Abbreviation: BMC Endocr Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Insulin Resistance*; Biomarkers/*analysis ; Blood Glucose/*analysis ; Diabetes Mellitus, Type 2/*diagnosis ; Glucose Intolerance/*diagnosis ; Insulin/*metabolism; Adolescent ; Adult ; Body Mass Index ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/metabolism ; Female ; Follow-Up Studies ; Glucose Intolerance/epidemiology ; Glucose Intolerance/metabolism ; Glucose Tolerance Test ; Humans ; Insulin Secretion ; Insulin-Secreting Cells/metabolism ; Insulin-Secreting Cells/pathology ; Male ; Prospective Studies ; Risk Factors ; Young Adult
    • Abstract:
      Background: We characterized in detail (oral and intravenous glucose tolerance tests (OGTT and IVGTT), euglycemic hyperinsulinemic clamp, adipose tissue biopsy), healthy first-degree relatives (FDR) of individuals with type 2 diabetes (T2D), to examine predictive factors for future development of impaired glucose tolerance (IGT) or T2D.
      Methods: Non-diabetic FDR (n = 138, mean age 40.5 ± 6.5 years, 57 % women) underwent an extended OGTT every 3 years to assess any deterioration in glucose tolerance status. Differences between groups were assessed by logistic fit for continuous variables and by contingency analysis for categorical variables. Multiple logistic regression analysis was applied to adjust for confounding variables.
      Results: At follow-up (mean 5.6 ± 2.4 years) 19 subjects had IGT and 4 had T2D. At baseline these 23 subjects had more family members with T2D, higher fasting plasma glucose, higher OGTT plasma glucose at 120 min, higher HbA1c, lower M-value and higher total cholesterol compared to subjects with normal glucose tolerance (NGT). There were significantly larger changes in weight, BMI, fasting plasma glucose, OGTT plasma glucose at 120 min and HbA1c in individuals developing IGT or T2D during the follow-up period than the subjects remaining NGT. Crude predictors of deteriorating glucose tolerance were age, family history of diabetes and of hypertension, OGTT plasma glucose levels at 60 min, 90 min, and 120 min, as well as serum bilirubin, ALP and creatinine (p-values <0.05). A multiple nominal logistic regression model revealed that male sex, low M-value and high physical exercise (p-values <0.05) predicted development of IGT/T2DM.
      Conclusion: In sum, genetically predisposed individuals for T2D with deteriorating glucose tolerance exhibit insulin resistance as well as beta-cell and signs of adipose tissue dysfunction, emphasizing the multifactorial pathophysiology in the development of IGT and T2D.
    • References:
      Diabetologia. 2000 Dec;43(12):1498-506. (PMID: 11151758)
      Diabetes. 2009 Apr;58(4):773-95. (PMID: 19336687)
      Diabet Med. 2001 Dec;18(12):984-90. (PMID: 11903398)
      Clin Chem. 2004 Jan;50(1):166-74. (PMID: 14709644)
      J Intern Med. 2004 Feb;255(2):273-9. (PMID: 14746565)
      Diabetologia. 2004 May;47(5):943-56. (PMID: 15105990)
      Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382)
      Am J Physiol. 1979 Sep;237(3):E214-23. (PMID: 382871)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      Am J Epidemiol. 1989 Jul;130(1):112-21. (PMID: 2787103)
      Stroke. 1995 Aug;26(8):1393-8. (PMID: 7631343)
      Ann Intern Med. 1999 Jul 6;131(1):27-31. (PMID: 10391812)
      Diabetologia. 2008 Feb;51(2):249-57. (PMID: 18060659)
      Curr Diabetes Rev. 2006 Nov;2(4):367-73. (PMID: 18220642)
      Diabetologia. 2008 May;51(5):816-20. (PMID: 18324385)
      Int J Biol Sci. 2008;4(4):208-14. (PMID: 18695734)
      Diabetologia. 2009 Nov;52(11):2435-44. (PMID: 19756484)
      Diabetologia. 2010 Aug;53(8):1709-13. (PMID: 20454776)
      Clin Chem. 2010 Aug;56(8):1252-60. (PMID: 20511445)
      Am J Physiol Endocrinol Metab. 2010 Sep;299(3):E506-15. (PMID: 20570822)
      Atherosclerosis. 2011 Jul;217(1):214-9. (PMID: 21474138)
      Diabetes. 2009 Jun;58(6):1255-6. (PMID: 19461116)
      Diabetes. 2009 Jul;58(7):1550-7. (PMID: 19351711)
      FASEB J. 2001 Apr;15(6):1101-3. (PMID: 11292681)
      Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E999-E1003. (PMID: 19622783)
      Obesity (Silver Spring). 2012 May;20(5):932-8. (PMID: 22240722)
      Diabetologia. 2013 Aug;56(8):1671-9. (PMID: 23680915)
      Diabetes Care. 2013 Nov;36(11):3607-12. (PMID: 24062330)
      PLoS Med. 2014 Feb;11(2):e1001602. (PMID: 24523667)
      Lancet. 2014 Mar 22;383(9922):1068-83. (PMID: 24315620)
      Clin Ther. 2014 Apr 1;36(4):494-506. (PMID: 24508418)
      Diabetes Care. 2014 Jul;37(7):1831-6. (PMID: 24760260)
      PLoS One. 2014;9(8):e105262. (PMID: 25148116)
      Mamm Genome. 2014 Oct;25(9-10):442-54. (PMID: 25146550)
      Exp Clin Endocrinol Diabetes. 2015 Jan;123(1):11-8. (PMID: 25314652)
      J Intern Med. 2015 May;277(5):540-51. (PMID: 25041575)
      Circulation. 2008 Aug 19;118(8):800-7. (PMID: 18678768)
      PLoS One. 2009;4(9):e7236. (PMID: 19789630)
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Insulin)
    • Publication Date:
      Date Created: 20150927 Date Completed: 20160818 Latest Revision: 20181217
    • Publication Date:
      20221213
    • Accession Number:
      PMC4583989
    • Accession Number:
      10.1186/s12902-015-0048-8
    • Accession Number:
      26407933